文献速递乳房整形与再造

乳房假体重建范式的转变:全国范围内直接置入假体趋势分析

Paradigm Shifts in Alloplastic Breast Reconstruction: A Nationwide Analysis of Direct-to-Implant Trends.
PubMed 文献 · Plast Reconstr Surg · 2023-06-19

该回顾性研究利用美国全国住院患者样本数据库,分析2010至2018年287093例假体乳房重建女性中43064例(15%)接受直接置入假体重建。研究期间直接置入假体比例显著增加(P=0.03),非白人及公共保险患者比例至2018年显著增加(P<0.05),Medicaid扩张州直接置入假体使用率为非扩张州的2.2倍,且住院费用显著低于分期手术(P=0.03)。

要点

  • 2010至2018年直接置入假体乳房重建比例显著增加(P=0.03)。
  • 2018年直接置入假体患者All Patient Refined Diagnosis Related Group风险评分显著高于2010年(P=0.02)。
  • 直接置入假体重建住院费用显著低于分期手术(P=0.03)。

核心结论

  • 过去十年直接置入假体乳房重建使用显著增加,得益于临床适应证扩大和保险覆盖改善,但某些差异仍然存在;进一步工作应调查差异驱动因素,以在临床适当时继续扩大直接置入假体重建。

研究设计与样本

  • 回顾性研究,使用美国全国住院患者样本数据库,分析2010至2018年直接置入假体重建,加权样本包括287093例接受假体乳房重建的女性,其中43064例(15%)接受直接置入假体重建。

主要发现

  • 研究期间直接置入假体手术比例显著增加(P=0.03),相对于分期和延迟假体手术。
  • 直接置入假体患者更年轻、更可能为白人和私人保险,但至2018年非白人、公共保险患者接受直接置入假体重建的比例显著增加(P<0.05)。
  • Medicaid患者中,扩张州直接置入假体使用率为非扩张州的2.2倍。
  • 2018年直接置入假体患者All Patient Refined Diagnosis Related Group风险评分显著高于2010年(P=0.02),表明临床适应证扩大。
  • 考虑扩张器置入和扩张器-假体交换时,直接置入假体重建的住院费用显著低于分期手术(P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-to-implant breast reconstruction is an attractive choice for appropriately selected patients, as a single-stage procedure can enhance global metrics of care. In an era of high-value health care, therefore, it is important to investigate use of such procedures. This study investigated direct-to-implant trends over the past decade on a nationwide basis. METHODS: This was a retrospective investigation of direct-to-implant reconstruction between 2010 and 2018 in the United States, using the National Inpatient Sample database. All study analyses were undertaken using Stata version 15.0. RESULTS: The weighted sample included 287,093 women who underwent implant-based reconstruction between 2010 and 2018, of whom 43,064 (15%) underwent direct-to-implant reconstruction. Across the study period, the proportion of direct-to-implant procedures increased significantly ( P = 0.03), relative to staged and delayed implant-based procedures. Although direct-to-implant patients were younger and more likely to be White and privately insured, the proportion of non-White, publicly insured patients undergoing direct-to-implant reconstruction increased significantly by 2018 ( P < 0.05). Furthermore, direct-to-implant use among Medicaid patients was 2.2 times the rate in Medicaid expansion states compared with nonexpansion states. Direct-to-implant patients had significantly higher All Patient Refined Diagnosis Related Group risk scores in 2018 than in 2010 ( P = 0.02), indicating expanding clinical indications for this procedure. Direct-to-implant reconstruction had significantly lower inpatient charges than staged procedures ( P = 0.03), when considering expander placement and expander-to-implant exchange. CONCLUSIONS: Overall, use of direct-to-implant breast reconstruction has significantly increased over the past decade, facilitated by expanding clinical indications and improved insurance coverage. However, certain disparities continue to exist. Further work should investigate drivers of disparities to allow continued expansion of direct-to-implant reconstruction as clinically appropriate. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Yesantharao PS, Arquette C, Cheesborough JE, et al. Paradigm Shifts in Alloplastic Breast Reconstruction: A Nationwide Analysis of Direct-to-Implant Trends. Plast Reconstr Surg. 2023. PMID: 37352460. doi:10.1097/PRS.0000000000010826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。